{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-035530","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2024-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.916209+00:00","generated_at":"2026-06-04T16:19:26.617922+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acura Pharmaceuticals receives $250k loan from major shareholder; warns of possible bankruptcy if no further funding","bullets":["Total note principal now $5,419,279 after 13th loan from AD Pharma (65% owner).","Loan matures March 31, 2024; funds used for operations only through mid-April.","Without additional funding by end of April, operations may cease or bankruptcy filed.","Default interest rate 7.5%; events include failure to pay, bankruptcy, inability to pay debts.","AD Pharma, controlled by Mr. Schutte, holds ~65% equity; Schutte personally owns ~13%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-035530","json":"https://secwatch.observer/filing/0001104659-24-035530.json","markdown":"https://secwatch.observer/filing/0001104659-24-035530.md","text":"https://secwatch.observer/filing/0001104659-24-035530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465924035530/0001104659-24-035530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465924035530/tm249122d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T16:19:26.617922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4bbf08e8ca457e1a0a92a59c38f99c8094e2876c","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $250,000 with Abuse Deterrent Pharma, LLC at 5.25% maturing March 31, 2024.","evidence_excerpt":"On March 14, 2024 we received a $250,000 loan from Abuse Deterrent Pharma, LLC (“AD Pharma”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465924035530/0001104659-24-035530-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$250,000"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Maturity","value":"March 31, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}